BackgroundVery few ethnoveterinary surveys have been conducted in central Europe. However, traditional knowledge on the use of medicinal plants might be an option for future concepts in treatment of livestock diseases. Therefore the aim of this study was to document and analyse the traditional knowledge and use of homemade herbal remedies for livestock by farmers in four Swiss cantons.MethodsResearch was conducted in 2012. Fifty farmers on 38 farms were interviewed with the aid of semistructured interviews. Detailed information about the plants used and their mode of preparation were documented as well as dosage, route of administration, category of use, origin of knowledge, frequency of use, and satisfaction with the treatment.ResultsIn total, 490 homemade remedies were collected. Out of these, 315 homemade remedies contained only one plant species (homemade single species herbal remedies, HSHR), which are presented in this paper. Seventy six species from 44 botanical families were mentioned. The most HSHR were quoted for the families of Asteraceae, Polygonaceae and Urticaceae. The plant species with the highest number of HSHRs were Matricaria recutita L., Calendula officinalis L., Rumex obtusifolius L. and Urtica dioica L. For each HSHR, one to eight different applications were enumerated. A total of 428 applications were documented, the majority of which were used to treat cattle. The main applications were in treatment of skin afflictions and sores, followed by gastrointestinal disorders and metabolic dysfunctions. Topical administration was most frequently used, followed by oral administration. In nearly half of the cases the knowledge on preparing and using herbal remedies was from forefathers and relatives. More than one third of the applications were used more than ten times during the last five years, and in about sixty percent of the cases, the last application was during the last year preceding the interviews.ConclusionsTraditional knowledge of farmers about the use of medicinal plants to treat livestock exists in north-eastern Switzerland. Homemade herbal remedies based on this knowledge are being used. The interviewed farmers were satisfied with the outcome of the applications.

PARP inhibitors (PARPi) have revolutionized the therapeutic landscape of epithelial ovarian cancer (EOC) treatment with outstanding benefits in regard to progression-free survival, especially in patients either carrying BRCA1/2 mutations or harboring defects in the homologous recombination repair system. Yet, it remains uncertain which PARPi to apply and how to predict responders when platinum sensitivity is unknown. To shed light on the predictive power of genes previously suggested to be associated with PARPi response, we systematically reviewed the literature and identified 79 publications investigating a total of 93 genes. The top candidate genes were further tested using a comprehensive CRISPR-Cas9 mutagenesis screening in combination with olaparib treatment. Therefore, we generated six constitutive Cas9+ EOC cell lines and profiled 33 genes in a CRISPR-Cas9 cell competition assay using non-essential (AAVS1) and essential (RPA3 and PCNA) genes for cell fitness as negative and positive controls, respectively. We identified only ATM, MUS81, NBN, BRCA2, and RAD51B as predictive markers for olaparib response. As the major survival benefit of PARPi treatment was reported in platinum-sensitive tumors, we next assessed nine top candidate genes in combination with three PARPi and carboplatin. Interestingly, we observed similar dropout rates in a gene and compound independent manner, supporting the strong correlation of cancer cell response to compounds that rely on DNA repair for their effectiveness. In addition, we report on CDK12 as a common vulnerability for EOC cell survival and proliferation without altering the olaparib response, highlighting its potential as a therapeutic target in EOC.

No abstract

Poly (ADP-ribose) polymerase (PARP)-inhibitors (PARPi) such as olaparib and niraparib are currently used as a treatment option for BRCA -deficient tumors and also show efficacy in platinum-sensitive tumors. However, resistance to PARPi occurs in numerous patients and in particular acquired PARPi resistance presents a major obstacle in the treatment of these tumors. In the present study, it was investigated whether stepwise exposure of ovarian cancer cells to escalating concentrations of olaparib produced subcells with acquired resistance to PARPi and/or acquired cross-resistance to platinum compounds, paclitaxel, and doxorubicin. To this aim, the sensitivity of fourteen ovarian cancer cell lines, including nine with TP53 -mutations and five carrying BRCA -mutations, to olaparib and niraparib was determined and a subset of seven cell lines was selected to investigate the potential of olaparib to produce resistance. It was identified that escalating olaparib did neither produce subcells with acquired PARPi-resistance nor did it produce acquired cross-resistance to platinum compounds, doxorubicin, and paclitaxel. This finding was independent of the cells' TP53 and BRCA mutation status. CRISPR- Cas9 mediated deletion of PARP1 did not affect sensitivity to PARPi, platinum compounds, doxorubicin, and paclitaxel. In addition, olaparib sensitivity correlated with niraparib sensitivity, but BRCA -mutated cells were not more sensitive to PARPi. Moreover, PARPi sensitivity associated with cross-sensitivity not only to platinum compounds but also to anthracylines, paclitaxel, and inhibitors of histone deacetylases. These in vitro data indicated that olaparib exposure is unlikely to produce an acquired resistance phenotype and that PARPi-sensitive ovarian cancer cells are also cross-sensitive to non-platinum and even to compounds not directly interacting with the DNA.